Skip To Main Content

Áreas terapeúticas

Descubra la más reciente actualización sobre la evidencia científica y los datos basados en la vida real que se han recopilado en el campo de la epidemiología. Esta información incluye detalles sobre la carga que estas enfermedades imponen a las personas y a la sociedad en general, así como los métodos de control que se están implementando para hacer frente a estas situaciones.

También se aborda el impacto económico que tienen enfermedades como asma grave, cardiovascular, dermatitis atópica, diabetes o enfermedades raras, etc., en la vida de nuestra población. Estos elementos son fundamentales para comprender la magnitud del problema y para desarrollar estrategias efectivas que ayuden a mejorar la salud pública.

Ordenar por

Patología

Limpiar filtro
  • Filtros
ERS 2025 Congress Highlights: Innovations in Respiratory Care and Biologics

ERS 2025 Congress Highlights: Innovations in Respiratory Care and Biologics

Explore key clinical insights and trial data from ERS 2025, including breakthroughs in biologics for asthma and COPD, pediatric asthma management, and AI-enabled respiratory innovation. Curated for healthcare professionals.

Kongres ESC 2025 - dr. Jose Fernandes Tunon dzieli się spostrzeżeniami na temat zmian w wytycznych dotyczących dyslipidemii. Zobacz teraz!

Kongres ESC 2025 - dr. Jose Fernandes Tunon dzieli się spostrzeżeniami na temat zmian w wytycznych dotyczących dyslipidemii. Zobacz teraz!

Tiêm Chủng Trong Thai Kỳ: Yếu Tố Quan Trọng Trong Chăm Sóc Sức Khỏe Thai Sản

Tiêm Chủng Trong Thai Kỳ: Yếu Tố Quan Trọng Trong Chăm Sóc Sức Khỏe Thai Sản

Discover the PulmoRounds: Where Respiratory Expertise Meets Clinical Practice

Discover the PulmoRounds: Where Respiratory Expertise Meets Clinical Practice

IL-4 and IL-13: the key and central drivers of type 2 inflammation<sup>1-2,6-7</sup>

IL-4 and IL-13: the key and central drivers of type 2 inflammation

Long Term Impact of AD and the Potential benefits of early intervention

Long Term Impact of AD and the Potential benefits of early intervention

This video explores the long-term, multi-dimensional burden of moderate-to-severe atopic dermatitis, highlighting its impact beyond the skin. It emphasizes the importance of early intervention targeting type 2 inflammation to alter the disease course and prevent long-term comorbidities.

The Cumulative Disease Burden of AD in Adult Patients

The Cumulative Disease Burden of AD in Adult Patients

This video highlights that the burden of atopic dermatitis in adults extends beyond skin symptoms, encompassing a broad spectrum of atopic and non-atopic comorbidities. These related conditions have a major impact on patient care, clinical decisions, and overall quality of life.

IL4 and IL13 important role in Chronic Itch

IL4 and IL13 important role in Chronic Itch

Discover the science beyond histamine: This video reveals how chronic itch in atopic dermatitis is predominantly mediated through non-histaminergic pathways. Learn how IL-4 and IL-13, key drivers of type 2 inflammation, create a critical intersection between inflammatory cascades and neural itch signaling. Understand the clinical implications of targeting these dual cytokines to simultaneously address both inflammation and the persistent itch cycle that significantly impacts patient quality of life.

The role of Epithelial Barrier Components in AD, insights and implications

The role of Epithelial Barrier Components in AD, insights and implications

This video provides insights into the key components and functions of the epithelial barriers in the skin. It highlights how barrier dysfunction plays a central role in the pathology of atopic dermatitis and emphasizes the importance of transepidermal water loss as a marker of barrier integrity and disease severity.

Clinical Indicators of COPD: A GOLD Guidelines Review

Clinical Indicators of COPD: A GOLD Guidelines Review

This video highlights the key insights from the 2025 Global Initiative for Chronic Obstructive Lung Disease (GOLD) report, presenting a clear, structured, and evidence-based approach to the diagnosis, assessment, and management of COPD.

Clinical Indicators of COPD: A GOLD Guidelines Review

Clinical Indicators of COPD: A GOLD Guidelines Review

This video highlights the key insights from the 2025 Global Initiative for Chronic Obstructive Lung Disease (GOLD) report, presenting a clear, structured, and evidence-based approach to the diagnosis, assessment, and management of COPD.

Clinical Indicators of COPD: A GOLD Guidelines Review

Clinical Indicators of COPD: A GOLD Guidelines Review

This video highlights the key insights from the 2025 Global Initiative for Chronic Obstructive Lung Disease (GOLD) report, presenting a clear, structured, and evidence-based approach to the diagnosis, assessment, and management of COPD.

Material diseñado por o para Sanofi Aventis de Colombia S.A., con fines educativos y dirigido a profesionales de la salud y personal administrativo del sector salud. Es estrictamente prohibido compartir este material con terceros.

Mayor información a disposición en el Departamento Médico:

En Colombia:

Sanofi-Aventis de Colombia S.A. Transversal 23 N° 97-73 - Edificio City Business. Piso 8. Bogotá D.C. Teléfono: 621 4400 - Fax: 744 4237

infomedica.colombia@sanofi.com

En Bolivia, Centro América y Caribe:

Sanofi-Aventis de Panamá S.A. Torre Evolution, piso 26, Calle 50 y Av. Aquilino de la Guardia Obarrio- Cuidad de Panamá, República de Panamá Telf.: (507) 382-9500. infomed.pac@sanofi.com

Sitio web: http://www.sanofi.com.pa/l/pa/sp/index.jsp

 

MAT-CO-2400825 V1.0 03/2024